Regeneron Antibody Drug a Game Changer for COVID-19 Prevention

When REGEN-COV treatment is administered, it can provide a “passive immunity” by limiting the ability of the coronavirus to develop into a symptomatic illness. Michael Nagle/Bloomberg via Getty Images

A new study found that REGEN-COV, a monoclonal antibody drug, can reduce the risk of coronavirus transmission by 81 percent.
Experts say these findings are very encouraging and suggest that REGEN-COV is highly effective at preventing the symptomatic transmission of the coronavirus.
They also say these findings mean healthcare professionals now have an option to speed antibody treatment against COVID-19.

One jab with Regeneron Pharmaceuticals’ monoclonal antibody drug reduced the infection risk of volunteers exposed to the coronavirus by 81 percent, the company announced April 12 in a press release.

This was a phase 3, double-blind, placebo-controlled trial. It was jointly run by the National Institute of Allergy and Infectious Diseases (NIAID).

Results showed that the drug (REGEN-COV), when administered beneath the skin by injection, reduced the risk of symptomatic infections by 81 percent in people who did not have an infection when the trial began.

Source: healthline